ArticleChemMedChem2026
Synthesis, Moleculer Modeling, and Carbonic Anhydrase Inhibitor Effects of Novel 1-(1-benzyl-2-oxoindolin-3-ylidene)-4-(3-sulfamoylphenyl)thiosemicarbazides.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we describe the synthesis of new 1-(1-benzyl-2-oxoindolin-3-ylidene)-4-(3-sulfamoylphenyl)thiosemicarbazides and evaluate their inhibitory activity against hCAs (6a-l). The inhibitory effects of compounds 6a-l were examined in vitro against hCA I, II, IX, and XII isoforms. Acetazolamide (AAZ) was employed as the standard reference compound in this study. The compounds 6a-l inhibited the tumor-associated hCA IX and XII isoenzymes at nanomolar levels, and showed weak inhibitory effects on the off-target hCA I and II isoenzymes. Selectivity index (SI) values of compounds 6a-l were determined to be significantly high for hCA IX and XII over hCA I and II compared to AAZ. Compound 6k (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.